Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:38 am
Share
Komipharm International Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 377.34 million compared to KRW 220.05 million a year ago. Net loss was KRW 981.8 million compared to KRW 2,437.9 million a year ago. Basic loss per share from continuing operations was KRW 13.6364 compared to KRW 34.5455 a year ago. Diluted loss per share from continuing operations was KRW 13.6364 compared to KRW 34.5455 a year ago. Basic loss per share was KRW 13.6364 compared to KRW 34.5455 a year ago.
For the nine months, sales was KRW 1,367.28 million compared to KRW 751.8 million a year ago. Net income was KRW 26.66 million compared to net loss of KRW 2,349.2 million a year ago. Basic earnings per share from continuing operations was KRW 0.9091 compared to basic loss per share from continuing operations of KRW 33.6364 a year ago. Basic earnings per share was KRW 0.9091 compared to basic loss per share of KRW 33.6364 a year ago.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
